Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation

H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $60.00.

Ananda Ghosh has given his Buy rating due to a combination of factors that highlight the promising potential of Structure Therapeutics’ oral GLP-1 asset, aleniglipron. The release of pivotal topline data from the Phase 2b ACCESS program has validated the company’s strategic approach, particularly the “low and slow” titration strategy, which has successfully mitigated gastrointestinal liabilities commonly associated with this class of drugs. The data revealed a significant 15.3% placebo-adjusted weight loss at the 240 mg dose, surpassing the efficacy benchmark and demonstrating a clean safety profile, which positions aleniglipron as a strong competitor in the market.
Ananda Ghosh’s rating is based on the transformative potential of aleniglipron, which not only meets but exceeds the efficacy of existing oral benchmarks. The validation of its “injectable-strength” efficacy and the innovative approach to addressing tolerability issues have shifted the investment thesis towards a scarcity-driven M&A arbitrage opportunity. The recent acquisition trends in the industry, such as Pfizer’s acquisition of Metsera, further support the re-rating of Structure’s asset. Additionally, the use of eDiaries in the study suggests that the reported gastrointestinal toxicity may be overestimated, further enhancing the commercial viability of aleniglipron in real-world settings.

In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $110.00 price target.